McAllister W A, Thompson P J, Al-Habet S M, Rogers H J
Br Med J (Clin Res Ed). 1983 Mar 19;286(6369):923-5. doi: 10.1136/bmj.286.6369.923.
Rifampicin is an inducer of hepatic drug metabolising enzymes. This results in interactions with several drugs including oral anticoagulants, hypoglycaemics, and contraceptives. Concurrent treatment with prednisolone and rifampicin is given when tuberculosis coexists with a disease that is sensitive to steroids, when the diagnosis is uncertain, or occasionally in the treatment of severe tuberculosis. Two patients with respiratory disease were treated with both drugs: their condition improved considerably after rifampicin was withdrawn. Seven patients were then studied to assess the effect of rifampicin on the pharmacokinetics of prednisolone. Overall, rifampicin increased the plasma clearance of prednisolone by 45% and reduced the amount of drug available to the tissues (area under the plasma concentration time curve) by 66%. The effectiveness of prednisolone may be considerably reduced when rifampicin and prednisolone are used in combination.
利福平是肝脏药物代谢酶的诱导剂。这会导致与多种药物发生相互作用，包括口服抗凝剂、降血糖药和避孕药。当结核病与对类固醇敏感的疾病并存、诊断不确定或偶尔在治疗严重结核病时，会同时使用泼尼松龙和利福平进行治疗。两名患有呼吸系统疾病的患者接受了这两种药物的治疗：停用利福平后，他们的病情有了显著改善。随后对7名患者进行了研究，以评估利福平对泼尼松龙药代动力学的影响。总体而言，利福平使泼尼松龙的血浆清除率提高了45%，并使组织可利用的药物量（血浆浓度-时间曲线下面积）减少了66%。联合使用利福平和泼尼松龙时，泼尼松龙的有效性可能会显著降低。
